GASTROINTESTINAL DRUGS ADVISORY COMMITTEE
June 27, 2000
Slides
Lotronex
Lotronex, Richard Kent MD, Glaxo Wellcome ppt html
IBS Burden of Illness, Ian M Gralnek MD MSHS, UCLA ppt html
Safety & Efficacy of Alosetron, Allen Mangel MD PhD, Glaxo Wellcome ppt html
Risk Management Plan, Elizabeth B Andrews PhD MPH, Glaxo Wellcome ppt html
Risk Management Program Communication Plan, J S Hull, Glaxo Wellcome ppt html
Conclusion, Richard Kent MD, Glaxo Wellcome ppt html
Benefit-Risk Reevaluation of Marketed Drugs, Victor F C Raczkowski MD MS, FDA ppt html
Lotronex Summary of Issues, Victor F C Raczkowski MD MS, FDA ppt html
Risk-Management Options, Victor F C Raczkowski MD MS, FDA ppt html
Lotronex, Hugo E Gallo-Torres MD PhD, FDA ppt html
Medical Guides, Nancy M Ostrove PhD, FDA ppt html
Postmarketing Drug safety and risk Intervention Studies, Evelyn M Rodriguez MD MPH, FDA ppt html